- Home
- RGT vs GALT Comparison
RGT vs GALT Comparison
Compare RGT & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGT
- GALT
- Stock Information
- Founded
- RGT 1986
- GALT 2000
- Country
- RGT United States
- GALT United States
- Employees
- RGT N/A
- GALT N/A
- Industry
- RGT Trusts Except Educational Religious and Charitable
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- RGT Finance
- GALT Health Care
- Exchange
- RGT Nasdaq
- GALT Nasdaq
- Market Cap
- RGT 80.2M
- GALT 83.5M
- IPO Year
- RGT N/A
- GALT N/A
- Fundamental
- Price
- RGT $11.93
- GALT $3.65
- Analyst Decision
- RGT
- GALT Buy
- Analyst Count
- RGT 0
- GALT 2
- Target Price
- RGT N/A
- GALT $6.00
- AVG Volume (30 Days)
- RGT 22.4K
- GALT 341.5K
- Earning Date
- RGT 01-01-0001
- GALT 08-12-2025
- Dividend Yield
- RGT 1.43%
- GALT N/A
- EPS Growth
- RGT N/A
- GALT N/A
- EPS
- RGT 0.92
- GALT N/A
- Revenue
- RGT N/A
- GALT N/A
- Revenue This Year
- RGT N/A
- GALT N/A
- Revenue Next Year
- RGT N/A
- GALT N/A
- P/E Ratio
- RGT $11.42
- GALT N/A
- Revenue Growth
- RGT N/A
- GALT N/A
- 52 Week Low
- RGT $7.84
- GALT $0.73
- 52 Week High
- RGT $11.08
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- RGT 38.16
- GALT 78.07
- Support Level
- RGT $12.18
- GALT $2.54
- Resistance Level
- RGT $12.39
- GALT $3.15
- Average True Range (ATR)
- RGT 0.11
- GALT 0.28
- MACD
- RGT -0.07
- GALT 0.06
- Stochastic Oscillator
- RGT 7.44
- GALT 82.22
About RGT Royce Global Value Trust Inc.
Royce Global Value Trust Inc is a diversified closed-end investment company. The fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples, and energy. Geographically, it has presence in the region of the United Kingdom, Japan, the United States, Canada, France, Hong Kong, and Germany.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.